Bright Minds Biosciences (DRUG) Corporate Presentation summary

Targeted serotonin receptor drug development

• Proprietary platform creates highly selective 5-HT2A and 5-HT2C agonists, avoiding 5-HT2B activity linked to cardiac risks.

• Lead programs focus on CNS and neuropsychiatric disorders, especially epilepsy and Prader-Willi syndrome.

• 5-HT2C agonists show superior efficacy in developmental and epileptic encephalopathies (DEE) compared to existing therapies.

• BMB-101 is a first-in-class, G protein-biased 5-HT2C agonist with validated mechanism and improved safety profile.

• BMB-105 targets Prader-Willi syndrome, addressing hyperphagia and neurobehavioral symptoms.

Clinical pipeline and data

• BMB-101 is in Phase 2 for absence seizures and DEE, with Phase 1 showing favorable safety and tolerability.

• Phase 1 data: no serious adverse events, most AEs transient and dose-related, lower somnolence and GI side effects than comparators.

• Phase 2 studies use weight-based dosing and ambulatory EEG to assess efficacy in seizure reduction and quality of life.

• BMB-105 is in Phase 1 for Prader-Willi syndrome, with a planned pivotal Phase 2/3 study.

• Preclinical data show efficacy of 5-HT2C agonists in reducing hyperphagia, aggression, and cognitive impairment in PWS models.

Market opportunity and competitive positioning

• Addressable refractory epilepsy market estimated at $21B, with $5.1B for absence epilepsy alone.

• BMB-101 is positioned as best-in-class for DEE and absence seizures, with potential for once-daily dosing and flexible administration.

• Prader-Willi syndrome market in the U.S. estimated at $4.6B, with only two approved drugs and significant unmet need.

• Company valuation is significantly lower than rare epilepsy peers, suggesting upside potential.

• Additional programs (BMB-201, BMB-202) target depression, anxiety, and pain with novel 5-HT2A agonists.